Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.2704 -0.0188 (-6.50%)
Streaming Delayed Price Updated: 10:20 AM EDT, Jun 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents. 
Via Talk Markets
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes that Adelia Has Reached Milestone Achievement
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities
Via Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Witnessing Advancement in R&D Pipeline
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Witnessing Advancement in R&D Pipeline
Via Investor Brand Network
Exposures Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business
Via Investor Brand Network
Exposures Product Safety
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
Cybin (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Provides 2021 Year End Summary
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming January Events
Via Investor Brand Network
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference
From Cybin Inc.
Via Business Wire
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies
Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cybin Receives Notice of Allowance from U.S. Patent Office
Cybin (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (... 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office for Exclusive Anxiety Disorder Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
From Cybin Inc.
Via Business Wire
Cybin Developing Safer, More Effective Psilocybin Therapies
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a... 
Via Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Developing Safer, More Effective Psilocybin Therapies
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Developing Safer, More Effective Psilocybin Therapies for Patients
Via Investor Brand Network
Cybin to Fund, Support Psychedelic Clinic at Manhattan Hospital
Company receives grant to fund clinic for marginalized, underserved NYC communities New clini... 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) to Fund, Support Psychedelic Clinic at Manhattan Hospital
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital
Via Investor Brand Network
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
Exposures Derivatives
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Moving Rapidly to Progress CYB003 Toward Clinical Development
Via Investor Brand Network
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.